China's Sinopharm has released its report on phase III clinical trials on inactivated COVID-19 vaccines.
The two vaccines, developed by its Wuhan and Beijing institutes, have an efficacy of 72.8% and 78.1%, respectively, according to a study published in The Journal of the American Medical Association (JAMA) on Wednesday.
Chinese inactivated vaccines effective against COVID-19 in phase-3 human trials: study
2021-05-27China's Sinopharm COVID-19 vaccine likely conducive to global vaccine accessibility: Indian newspape
2021-05-13
